

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported): April 8, 2026

TECOGEN INC.

(Exact Name of Registrant as Specified in Charter)

Delaware

(State or Other Jurisdiction of Incorporation)

001-36103

(Commission File Number)

04-3536131

(IRS Employer Identification No.)

**76 Treble Cove Road, Building 1
North Billerica, Massachusetts 01862**

(Address of Principal Executive Offices and Zip Code)

(781) 466-6400

(Registrant's telephone number, including area code)

Securities registered or to be registered pursuant to Section 12(b) of the Act.

Title of each class	Trading Symbol	Name of exchange on which registered
Common Stock, \$0.001 par value per share	TGEN	NYSE American, LLC

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Item 8.01. Other Events.

On April 8, 2026, Tecogen Inc., a Delaware corporation (the “Company”) agreed to extend the term of the Advisory Agreement dated January 18, 2018, as amended on July 22, 2019 and July 19, 2023, between the Company and Mr. John N. Hatsopoulos (the “Advisory Agreement”) through March 31, 2028. The extension of the term of the Advisory Agreement was approved by Unanimous Written Consent of the Company’s Board of Directors on April 7, 2026. A copy of the letter agreement extending the Advisory Agreement is attached hereto as Exhibit 99.1.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

<u>Exhibit</u>	<u>Description</u>
99.1	<u>Letter Agreement dated April 8, 2026 extending the term of the Advisory Agreement between Tecogen Inc. and John N. Hatsopoulos.</u>

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf by the undersigned, hereunto

TECOGEN INC.

By: /s/ Abinand Rangesh

Abinand Rangesh, Chief Executive Officer

duly authorized. April 8, 2026



April 8, 2026

Mr. John Hatsopoulos
76 Treble Cove Rd., Bldg. 1
N. Billerica, MA 01862

Re: Extension of Advisory Agreement

Dear John:

Tecogen has agreed to extend the term of your Advisory Agreement dated January 3, 2018, as amended, through March 31, 2028.

Please confirm your agreement by signing a copy of this letter and returning it to me.

We appreciate and value your continued contributions to Tecogen.

Sincerely,

Abinand Rangesh
CEO

A handwritten signature in black ink, appearing to read "Abinand Rangesh", written over a horizontal line.

AGREED:

A handwritten signature in black ink, appearing to read "John N. Hatsopoulos", written over a horizontal line.

John N. Hatsopoulos

